Table 1 Baseline characteristics of individuals with smoldering multiple myeloma and their matched MGUS-free comparators and matched MGUS individuals.
From: Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study
SMM | MGUS-free comparators | MGUS | |
---|---|---|---|
Total, N | 188 | 810 | 188 |
Age (years), median (IQR) | 69 (63–76) | 69 (62–76) | 69 (63–77) |
Sex, N (%) | |||
Female | 73 (39%) | 310 (38%) | 73 (39%) |
Male | 115 (61%) | 500 (62%) | 115 (61%) |
Follow-up (years), median (IQR) | 2.16 (1.26–4.02) | 3.73 (2.26–4.32) | 2.72 (1.37–4.06) |
M-protein isotype, N (%) | |||
Biclonal | 18 (9.5%) | - | 13 (7%) |
IgA | 45 (24%) | - | 9 (5%) |
IgG | 97 (51.5%) | - | 114 (60%) |
IgM | 2 (1%) | - | 28 (15%) |
Light-chain MGUS | 26 (14%) | - | 24 (13%) |
M-protein level (g/L), median (IQR) | 5.9 (3.3–10.7) | - | 2.2 (1.4–3.7) |
Hemoglobin (g/L), median (IQR) | 138 (128–147) | 142 (133–151) | 141 (131–149) |
Total calcium (mmol/L), median (IQR) | 2.37 (2.31–2.43) | 2.36 (2.29–2.41) | 2.37 (2.30–2.43) |
Creatinine (µmol/L), median (IQR) | 87 (76-101) | 84 (70–96) | 86 (74–104) |
Immunoparesis, N (%) | |||
1 uninvolved Ig < normal ref. | 86 (46%) | 77 (9.5%) | 42 (22%) |
25% reduction from normal ref. in 1 Ig | 51 (27%) | 24 (3.0%) | 19 (10%) |
>1 Ig under normal ref. | 32 (17%) | 7 (0.9%) | 10 (5.3%) |
Risk factors (2-20-20 model), N (%) | |||
M-protein >2 g/L | 3 (1.6%) | - | - |
FLC ratio >20 or <0.05 | 21 (11%) | - | - |
BMPC > 20% | 28 (15%) | - | - |
SMM risk stratification, N (%) | |||
0 risk factors: Low risk | 143 (76%) | - | - |
1 risk factor: Intermediate risk | 39 (21%) | - | - |
2-3 risk factors: High risk | 6 (3%) | - | - |